ReviewCancer gene therapy2007
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
Review in Cancer gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- G3139 (Genasense) in patients with advanced merkel cell carcinoma.American journal of clinical oncology · 2009Trial
- Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.International journal of molecular sciences · 2021Review
- Autophagy upregulation and apoptosis downregulation in DAHP and triptolide treated cerebral ischemia.Mediators of inflammation · 2015Article
- Autophagy activation aggravates neuronal injury in the hippocampus of vascular dementia rats.Neural regeneration research · 2014Article
- A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.Investigational new drugs · 2013Article
- Article
- Article
- Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1.Journal of translational medicine · 2012Article
- The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.Leukemia · 2011Article
- The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.Oncotarget · 2010Review
- Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity.The Journal of biological chemistry · 2010Article
- The mitochondrial death pathway: a promising therapeutic target in diseases.Journal of cellular and molecular medicine · 2009Review
- Regulated cell death pathways: new twists in modulation of BCL2 family function.Molecular cancer therapeutics · 2009Review
- Bcl2 family proteins in carcinogenesis and the treatment of cancer.Apoptosis : an international journal on programmed cell death · 2009Article
- Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Review
- Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.Journal of virology · 2008Article
- Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Drug discovery today · 2008Review
- Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?Cell death and differentiation · 2008Review
- The apoptosome: emerging insights and new potential targets for drug design.Pharmaceutical research · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bcl-2 is an oncoprotein that plays a critical role in inhibiting apoptotic cell death in the mitochondria-dependent pathway in cancer chemotherapy. As a strategy for blocking Bcl-2 for enhancement of the chemotherapeutic effect, antisense Bcl-2 (AS Bcl-2; G3139, oblimersen sodium, Genasense) has shown promise, and there are several ongoing clinical studies with hematological malignancies as well as solid tumors. Although several preclinical and clinical studies have shown the therapeutic efficacy of Bcl-2 in combination with an anticancer drug as a chemosensitizer, in clinical trials the downregulation of Bcl-2 has not been observed with a high frequency in tumor cells. Nevertheless, previous studies showed nonantisense effects such as production of reactive oxygen species and immunostimulatory action through cytosine-phosphate-guanosine-motif in the antisense oligodeoxynucleotides. Further, Bcl-2 is able to inhibit Beclin 1-dependent autophagic cell death, which is a nonapoptotic cell death. The current status and future directions of AS Bcl-2 and the potential mechanisms for multiple roles that Bcl-2 has in cancer therapy are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.